The National Institutes of Health has named a panel of experts that will lead President Barack Obama's Precision Medicine Initiative.
Heading the panel will be co-chairs Richard Lifton, MD, PhD, professor of genetics, professor of medicine and chair of the genetics department at New Haven, Conn.-based Yale University School of Medicine; Bray Patrick-Lake, director of patient engagement at Durham, N.C.-based Duke University; and Kathy Hudson, PhD, deputy director of science, outreach and policy at NIH.
The panel also includes Esteban Gonzalez Burchard, MD, PhD, from the University of California, San Francisco; Tony Coles, MD, of Yumanity Therapeutics; Sir Rory Collins from the University of Oxford; Andrew Conrad, PhD, of Google X; and Josh Denny, MD, from Vanderbilt University, along with 11 other members.
According to the report, the panel will seek input from stakeholders in the Precision Medicine Initiative and define the vision for building the national participation group for the initiative. The panel will help define what can be learned from a study of this scale and scope, issues that need to be addressed and considered as part of the study design and five- and 10-year timelines for what success would look like. The panel will act as a Working Group of the Advisory Committee to the NIH Director Francis Collins and will deliver a preliminary report in September that will clarify the impact individual differences have on people's health.